AtriCure, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $53M TTM free cash flow base (essentially unlevered given minimal debt); 13% annual growth years 1-5 consistent with 2026 guidance of $602-610M revenue, 8% years 6-10; 9% discount rate; 3% terminal growth; $105.4M net cash; 50.87M shares outstanding.

Reasoning: AtriCure is a profitable, fast-growing cardiac ablation medtech company with a management target of roughly 13% revenue CAGR through 2030, making a standard growth-medtech DCF with tapered later-year growth appropriate.